Equities

Organogenesis Holdings Inc

Organogenesis Holdings Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)4.13
  • Today's Change0.11 / 2.74%
  • Shares traded581.53k
  • 1 Year change+59.46%
  • Beta1.7160
Data delayed at least 15 minutes, as of Nov 22 2024 19:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

  • Revenue in USD (TTM)455.04m
  • Net income in USD-7.38m
  • Incorporated2018
  • Employees862.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SS Innovations International Inc16.39m-27.82m512.22m239.00--36.90--31.25-0.1638-0.16380.09620.08130.52981.674.2268,573.09-89.92-161.38-160.65-449.7631.96-79.79-169.74-495.770.9225-39.810.4746-------846.31--159.31--
Monte Rosa Therapeutics Inc14.98m-119.39m513.00m103.00--2.49--34.26-1.83-1.830.22153.350.0528--33.69112,594.00-42.10---47.48-------797.26------0.00-------24.75------
Alumis Inc0.00-238.77m513.57m145.00--1.47-----4.52-4.520.006.40----------------------------0.00-------38.47------
Third Harmonic Bio Inc0.00-39.20m515.92m51.00--1.74-----0.9694-0.96940.006.590.00----0.00-13.36---13.66--------------0.00------12.32------
Mind Medicine (MindMed) Inc0.00-97.80m519.92m57.00--2.21-----1.99-1.990.003.210.00----0.00-42.40---49.28--------------0.0849-------68.55------
Sana Biotechnology Inc0.00-305.81m524.68m328.00--1.79-----1.41-1.410.001.310.00----0.00-51.36-38.99-56.78-42.70------------0.00-------5.11--112.71--
Astria Therapeutics Inc0.00-100.04m527.01m59.00--2.14-----2.09-2.090.006.050.00----0.00-36.02-64.48-37.72-68.34------------0.00-------40.62------
IGM Biosciences Inc2.92m-219.84m527.34m198.00--6.69--180.72-3.65-3.650.04841.330.0075----13,026.79-56.45-44.66-63.54-48.20-----7,534.03-23,668.96----0.00--99.25---11.45--73.48--
Organogenesis Holdings Inc455.04m-7.38m532.95m862.00--1.9156.651.17-0.0567-0.05673.432.101.004.094.78527,886.30-1.625.46-1.976.9075.2974.94-1.624.812.746.560.18750.00-3.9417.49-68.16--67.34--
Ironwood Pharmaceuticals, Inc.378.42m-2.46m534.49m267.00------1.41-0.016-0.0162.39-1.950.8284--3.771,417,296.00-0.6832-4.54-1.07-5.20-----0.8248-7.81--3.882.08--7.835.02-672.50--160.10--
Annexon Inc0.00-117.50m546.23m84.00--1.65-----1.04-1.040.003.140.00----0.00-40.34-44.06-43.09-46.93------------0.00------5.43--62.56--
Humacyte Inc0.00-152.87m547.63m183.00---------1.34-1.340.00-0.53170.00----0.00-115.74---134.05-------------27.44-----100.00---825.83------
Grail Inc-100.00bn-100.00bn550.38m1.37k--0.2102----------77.93-----------47.45---48.55-------5,118.86--------67.61--72.85---4.22--
MBX Biosciences Inc-100.00bn-100.00bn551.72m36.00--2.03----------8.13----------------------------0.00-------24.60------
Kezar Life Sciences Inc0.00-95.78m555.97m58.00--0.4148-----13.15-13.150.0018.370.00----0.00-46.34-32.54-50.90-34.09-------4,308.11----0.0711-------49.28--10.08--
Savara Inc0.00-82.94m556.05m37.00--2.78-----0.4452-0.44520.001.170.00----0.00-39.41-36.86-41.56-39.54-------102,587.50----0.1175-------43.38--15.91--
Data as of Nov 22 2024. Currency figures normalised to Organogenesis Holdings Inc's reporting currency: US Dollar USD

Institutional shareholders

36.60%Per cent of shares held by top holders
HolderShares% Held
Morgan Stanley & Co. LLCas of 30 Sep 202411.89m8.97%
Soleus Capital Management LP (Investment Management)as of 30 Sep 202411.84m8.93%
DWS Investments (UK) Ltd.as of 30 Sep 20244.84m3.65%
BlackRock Fund Advisorsas of 30 Sep 20244.77m3.60%
The Vanguard Group, Inc.as of 30 Sep 20243.61m2.72%
Acadian Asset Management LLCas of 30 Sep 20243.02m2.28%
AQR Capital Management LLCas of 30 Sep 20242.71m2.05%
Dimensional Fund Advisors LPas of 30 Sep 20242.18m1.64%
Assenagon Asset Management SA (Germany)as of 30 Sep 20241.92m1.45%
Geode Capital Management LLCas of 30 Sep 20241.75m1.32%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.